In a study involving a patient with CLL who achieved complete remission following treatment with CAR T cells targeting the CD19 protein, it was observed that the CAR T cells originated from a ten-eleven translocation 2 (TET2)-targeted insertional mutagenesis event, exhibited Tcm phenotype at the peak of their expansion (187). Here, TET2 is linked to B-cell chronic lymphocytic leukemia.